ELTX

Elicio Therapeutics, Inc. ELTX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $28.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$15.32M total
Knoll Capital Management, LLC
$4.74M+92.1%
BlackRock, Inc.
$3.00M+1413.9%
VANGUARD CAPITAL MANAGEMENT LLC
$2.24M+10.3%
GEODE CAPITAL MANAGEMENT, LLC
$1.22M+130.4%
STATE STREET CORP
$701.5K+254.4%
NORTHERN TRUST CORP
$508.9K+117.9%
Ikarian Capital, LLC
$391.0KNew
VANGUARD PORTFOLIO MANAGEMENT LLC
$347.6KNew
VANGUARD FIDUCIARY TRUST CO
$344.3K+27.3%
ALLIANCEBERNSTEIN L.P.
$317.8KNew
UBS Group AG
$158.0K+19.7%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$124.0KNew
BOOTHBAY FUND MANAGEMENT, LLC
$120.0KNew
MORGAN STANLEY
$99.9K-21.2%
Leonteq Securities AG
$78.2KNew
Nuveen, LLC
$69.9KNew
CITIGROUP INC
$69.3KNew
Bank of New York Mellon Corp
$62.1KNew
NEW YORK STATE COMMON RETIREMENT FUND
$55.5KNew
MEYER HANDELMAN CO
$54.3K0.0%
HighTower Advisors, LLC
$53.4K+22.4%
RAYMOND JAMES FINANCIAL INC
$49.7K+14.6%
DEUTSCHE BANK AG\
$49.5KNew
WELLS FARGO & COMPANY/MN
$46.2KNew
PRICE T ROWE ASSOCIATES INC /MD/
$42.0KNew
See all 48 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ELTX

Earnings Per Share

13fpro.ai/company/ELTX

Loading ratio trend…

ELTX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Elicio Therapeutics, Inc.'s annual filings on SEC EDGAR.

Elicio Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$2.3M$-28.2M—
FY 2021$28.3M$-54.6M-138.8%
FY 2020$2.9M$-80.1M—
Source: ELTX filings on SEC EDGAR →

ELTX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Elicio Therapeutics, Inc. (ELTX): stock profile, AI score and financials

Elicio Therapeutics, Inc. (ELTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ELTX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $28.3m in revenue and is scored on the micro-cap board instead. Top institutional holders of ELTX by reported 13-F value include Knoll Capital Management, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ELTX trades on the Nasdaq exchange and files with the SEC under CIK 1601485. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elicio Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1601485 →